Fig. 7: PHLDA1/2 are highly expressed in cancers harboring ERK activating oncogenes.
a Oncogenic ERK signaling induces simultaneous PHLDA1/2 expression. HEK293 cells were stimulated with EGF, TPA, or insulin with or without trametinib for the indicated times. The cell lysates were probed for PHLDA1/2 expression, and for the phosphorylation states and protein levels of ERK and AKT by immunoblotting. b HEK293 cells were treated with various concentration of TPA for 6 h, and the cell lysates were analyzed as in (a). The intensity of the PHLDA1/2 bands was quantified (bottom graphs). c, d PHLDA1/2 mRNA and protein expression levels in HEK293 cells stably expressing NRasG12V or BRafV600E were assessed using qRT-PCR (c) and by immunoblotting (d), respectively. Where indicated, the cells were pretreated with the MEK inhibitor, trametinib. e Immunoblot analysis of PHLDA1/2 expression in various cancer cell lines harboring the indicated oncogenes. Where indicated, cells were pretreated with the EGFR inhibitor (canertinib), the BRaf inhibitor (vemurafenib), or trametinib. b, c Data are mean ± SEM from three independent experiments. P-values were assessed using one-way ANOVA followed by Tukey’s multiple comparisons test. Source data are provided as a Source Data file.
